Clinical and mental health characteristics among patients receiving medications for opioid use disorder treatment versus patients receiving low- and high-dose opioids when referred for pain management - Scorecard - MDSpire
Advertisement
Clinical and mental health characteristics among patients receiving medications for opioid use disorder treatment versus patients receiving low- and high-dose opioids when referred for pain management
Clinical Scorecard: Comparative Analysis of Clinical and Psychological Profiles in Patients Undergoing Opioid Use Disorder Treatment Versus Those on Low- and High-Dose Opioids for Pain Management
At a Glance
Category
Detail
Condition
Chronic pain with concurrent opioid use disorder or prescription opioid analgesic use
Key Mechanisms
Opioid agonist treatment (methadone, buprenorphine) for OUD; prescription opioids at varying doses affecting pain intensity, mental health, and multimorbidity
Target Population
Adults attending Australian pain management services receiving opioid agonist treatment or prescription opioid analgesics
Care Setting
Australian pain management clinics and services
Key Highlights
Patients on opioid agonist treatment (OAT) and those on high-dose opioids (>100 mg oral morphine equivalent) exhibit more severe mental health symptoms and longer pain duration than low-dose opioid users (<40 mg).
Compared to high-dose opioid users, OAT patients report lower pain intensity but higher multimorbidity, anxiety severity, and pain catastrophizing.
Tailored multidisciplinary pain management and mental health treatment are essential for patients receiving OAT.
Guideline-Based Recommendations
Diagnosis
Assess opioid use type and dose (OAT vs. low- or high-dose prescription opioids) in chronic pain patients.
Evaluate mental health symptoms including anxiety and catastrophizing thoughts.
Screen for multimorbidity and socioeconomic disadvantage.
Management
Implement multidisciplinary pain management tailored to patients on OAT.
Address mental health comorbidities concurrently with pain treatment.
Recognize limited analgesic efficacy of OAT medicines and potential opioid-induced hyperalgesia.
Monitoring & Follow-up
Regularly monitor pain intensity and mental health symptom severity.
Track opioid dosing and adjust treatment plans accordingly.
Evaluate treatment outcomes within multidisciplinary teams.
Risks
Risk of undertreated pain in patients on OAT.
Potential for opioid-induced hyperalgesia with prolonged opioid exposure.
Increased vulnerability due to multimorbidity and mental health disorders.
Patient & Prescribing Data
42,182 adult patients attending Australian pain services between 2016 and 2021, including 1,016 on OAT and 7,122 on high-dose opioids.
OAT patients have distinct clinical profiles with lower pain intensity but greater mental health burden and multimorbidity compared to high-dose opioid users, highlighting the need for integrated care approaches.
Clinical Best Practices
Incorporate comprehensive mental health assessment and treatment in pain management for patients on OAT.
Use multidisciplinary teams to address complex needs of patients with concurrent chronic pain and OUD.
Avoid reliance solely on opioid dose escalation; consider psychosocial and physical comorbidities.
Recognize and manage pain catastrophizing to improve patient outcomes.
In a target-trial emulation of more than 600,000 veterans, GLP-1 RA initiators saw fewer new substance use disorders—and patients with existing SUDs had fewer overdoses, hospitalizations, and deaths.
